Israel’s IceCure Adds Oregon Clinical Site to Breast Cancer Study
Israeli company IceCure Medical is adding Legacy Health in Oregon as a clinical site for its FDA-approved study of the ProSense cryoablation system for breast.
Israeli company IceCure Medical is adding Legacy Health in Oregon as a clinical site for its FDA-approved study of the ProSense cryoablation system for breast.
Israeli firm IceCure Medical has gained China's National Medical Products Administration approval for its ProSense cryoablation system, expanding cancer.
Israeli firm IceCure Medical partners with Scovas Medical for exclusive distribution of its ProSense cryoablation cancer treatment in the Netherlands.
IceCure Medical's tumor-freezing ProSense technology is gaining commercial traction in Brazil for breast, lung, kidney, and musculoskeletal tumors.
IceCure Medical's ProSense cryoablation, a minimally invasive breast cancer treatment, is now under FDA review in a post-market study called "ChoICE.".